New and Emerging Options in Osteoporosis: Improving Strategies and Outcomes in PracticePreassessmentPlease take this brief survey to share your experience and knowledge on obesity. Your input will help us as we prepare the program. The live event will take place Monday, March 19, 2018, from 6:00–9:00 PM PST at the McCormick Place South, Room S100A. To be entered into the drawing for a $50 gift card, please provide your e-mail. * How many years have you been in clinical practice? * - Select -< 55-1011-20> 20Not in practice If you are in practice, what is the average breakdown of your patients in terms of the following endocrine disorders? * <10%10-25%25-50%50-75%>75%NA Diabetes Diabetes - <10% Diabetes - 10-25% Diabetes - 25-50% Diabetes - 50-75% Diabetes - >75% Diabetes - NA Thyroid Thyroid - <10% Thyroid - 10-25% Thyroid - 25-50% Thyroid - 50-75% Thyroid - >75% Thyroid - NA Osteoporosis Osteoporosis - <10% Osteoporosis - 10-25% Osteoporosis - 25-50% Osteoporosis - 50-75% Osteoporosis - >75% Osteoporosis - NA Neuroendocrinology Neuroendocrinology - <10% Neuroendocrinology - 10-25% Neuroendocrinology - 25-50% Neuroendocrinology - 50-75% Neuroendocrinology - >75% Neuroendocrinology - NA Other Other - <10% Other - 10-25% Other - 25-50% Other - 50-75% Other - >75% Other - NA Among the patients in your practice with metabolic bone diseases, what is the percentage in each category * <10%10-25%25-50%50-75%>75%NA Osteoporosis Osteoporosis - <10% Osteoporosis - 10-25% Osteoporosis - 25-50% Osteoporosis - 50-75% Osteoporosis - >75% Osteoporosis - NA Primary Hyperparathyroidism Primary Hyperparathyroidism - <10% Primary Hyperparathyroidism - 10-25% Primary Hyperparathyroidism - 25-50% Primary Hyperparathyroidism - 50-75% Primary Hyperparathyroidism - >75% Primary Hyperparathyroidism - NA Hypoparathyroidism Hypoparathyroidism - <10% Hypoparathyroidism - 10-25% Hypoparathyroidism - 25-50% Hypoparathyroidism - 50-75% Hypoparathyroidism - >75% Hypoparathyroidism - NA Chronic Kidney Disease Chronic Kidney Disease - <10% Chronic Kidney Disease - 10-25% Chronic Kidney Disease - 25-50% Chronic Kidney Disease - 50-75% Chronic Kidney Disease - >75% Chronic Kidney Disease - NA Other Other - <10% Other - 10-25% Other - 25-50% Other - 50-75% Other - >75% Other - NA Among your patients with osteoporosis, what percentage is in each category: * <10%10-25%25-50%50-75%>75%NA Postmenopausal Postmenopausal - <10% Postmenopausal - 10-25% Postmenopausal - 25-50% Postmenopausal - 50-75% Postmenopausal - >75% Postmenopausal - NA Postmenopausal (over 80) Postmenopausal (over 80) - <10% Postmenopausal (over 80) - 10-25% Postmenopausal (over 80) - 25-50% Postmenopausal (over 80) - 50-75% Postmenopausal (over 80) - >75% Postmenopausal (over 80) - NA Premenopausal Premenopausal - <10% Premenopausal - 10-25% Premenopausal - 25-50% Premenopausal - 50-75% Premenopausal - >75% Premenopausal - NA Male Male - <10% Male - 10-25% Male - 25-50% Male - 50-75% Male - >75% Male - NA Glucocorticoid-induced Glucocorticoid-induced - <10% Glucocorticoid-induced - 10-25% Glucocorticoid-induced - 25-50% Glucocorticoid-induced - 50-75% Glucocorticoid-induced - >75% Glucocorticoid-induced - NA Other secondary causes Other secondary causes - <10% Other secondary causes - 10-25% Other secondary causes - 25-50% Other secondary causes - 50-75% Other secondary causes - >75% Other secondary causes - NA Approximately what percentage of your patients: * <10%10-25%25-50%50-75%>75%NA Feel that appropriate calcium and vitamin D are important to their overall skeletal Feel that appropriate calcium and vitamin D are important to their overall skeletal - <10% Feel that appropriate calcium and vitamin D are important to their overall skeletal - 10-25% Feel that appropriate calcium and vitamin D are important to their overall skeletal - 25-50% Feel that appropriate calcium and vitamin D are important to their overall skeletal - 50-75% Feel that appropriate calcium and vitamin D are important to their overall skeletal - >75% Feel that appropriate calcium and vitamin D are important to their overall skeletal - NA Feel that appropriate exercise is important to their overall skeletal health Feel that appropriate exercise is important to their overall skeletal health - <10% Feel that appropriate exercise is important to their overall skeletal health - 10-25% Feel that appropriate exercise is important to their overall skeletal health - 25-50% Feel that appropriate exercise is important to their overall skeletal health - 50-75% Feel that appropriate exercise is important to their overall skeletal health - >75% Feel that appropriate exercise is important to their overall skeletal health - NA Concerned in any way Concerned in any way - <10% Concerned in any way - 10-25% Concerned in any way - 25-50% Concerned in any way - 50-75% Concerned in any way - >75% Concerned in any way - NA Who would prefer not to use any pharmacological agent Who would prefer not to use any pharmacological agent - <10% Who would prefer not to use any pharmacological agent - 10-25% Who would prefer not to use any pharmacological agent - 25-50% Who would prefer not to use any pharmacological agent - 50-75% Who would prefer not to use any pharmacological agent - >75% Who would prefer not to use any pharmacological agent - NA In which situations do you use FRAX: * YesNo T-score < -2.5 T-score < -2.5 - Yes T-score < -2.5 - No T-score between -2.5 and -1.1 T-score between -2.5 and -1.1 - Yes T-score between -2.5 and -1.1 - No T-score > -1.0 T-score > -1.0 - Yes T-score > -1.0 - No Previous fragility fracture Previous fragility fracture - Yes Previous fragility fracture - No Ongoing pharmacological therapy Ongoing pharmacological therapy - Yes Ongoing pharmacological therapy - No Among your patients what do you feel is the biggest drawbacks to pharmacological therapy of osteoporosis: * Not at all concernedSlightly concernedSomewhat concernedModerately concernedExtremely concerned Real and perceived side effects Real and perceived side effects - Not at all concerned Real and perceived side effects - Slightly concerned Real and perceived side effects - Somewhat concerned Real and perceived side effects - Moderately concerned Real and perceived side effects - Extremely concerned Expense Expense - Not at all concerned Expense - Slightly concerned Expense - Somewhat concerned Expense - Moderately concerned Expense - Extremely concerned Challenge to comply with dosing instructions Challenge to comply with dosing instructions - Not at all concerned Challenge to comply with dosing instructions - Slightly concerned Challenge to comply with dosing instructions - Somewhat concerned Challenge to comply with dosing instructions - Moderately concerned Challenge to comply with dosing instructions - Extremely concerned Perception of Efficacy Perception of Efficacy - Not at all concerned Perception of Efficacy - Slightly concerned Perception of Efficacy - Somewhat concerned Perception of Efficacy - Moderately concerned Perception of Efficacy - Extremely concerned Other Other - Not at all concerned Other - Slightly concerned Other - Somewhat concerned Other - Moderately concerned Other - Extremely concerned What level of patient resistance do you encounter when you prescribe the following class of drugs? * Great resistanceSome resistanceLittle resistanceMinimal resistanceNo resistance Oral bisphosphonates Oral bisphosphonates - Great resistance Oral bisphosphonates - Some resistance Oral bisphosphonates - Little resistance Oral bisphosphonates - Minimal resistance Oral bisphosphonates - No resistance Intravenous bisphosphonates Intravenous bisphosphonates - Great resistance Intravenous bisphosphonates - Some resistance Intravenous bisphosphonates - Little resistance Intravenous bisphosphonates - Minimal resistance Intravenous bisphosphonates - No resistance Anabolic drugs Anabolic drugs - Great resistance Anabolic drugs - Some resistance Anabolic drugs - Little resistance Anabolic drugs - Minimal resistance Anabolic drugs - No resistance Rank L inhibitors Rank L inhibitors - Great resistance Rank L inhibitors - Some resistance Rank L inhibitors - Little resistance Rank L inhibitors - Minimal resistance Rank L inhibitors - No resistance Estrogen (in postmenopausal women) Estrogen (in postmenopausal women) - Great resistance Estrogen (in postmenopausal women) - Some resistance Estrogen (in postmenopausal women) - Little resistance Estrogen (in postmenopausal women) - Minimal resistance Estrogen (in postmenopausal women) - No resistance How often do you have to intercede on behalf of your patients when the drug you have prescribed is denied by the provider: * - Select -OftenOccasionallyRarelyVirtually never Do you follow established guidelines for measurement of bone mineral density? (e.g. all postmenopausal women > 65 or < 65 with established risk factors) * AlwaysMost of the TimeOccasionallyRarelyThe guidelines are not very useful Do you follow established guidelines for measurement of bone mineral density? Do you follow established guidelines for measurement of bone mineral density? - Always Do you follow established guidelines for measurement of bone mineral density? - Most of the Time Do you follow established guidelines for measurement of bone mineral density? - Occasionally Do you follow established guidelines for measurement of bone mineral density? - Rarely Do you follow established guidelines for measurement of bone mineral density? - The guidelines are not very useful Do you adhere to the general guidelines that all patients whose lumbar spine, total hip, or femoral neck T-score is < -2.5 should be treated with a pharmacological agent? * - Select -YesNo Leave this field blank
